Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical response to everolimus in a patient with Hodgkin's lymphoma harboring a TSC2 mutation.

Blood cancer journal - 13 May 2016

Perini G F, Campregher P V, Ross J S, Ali S, Hamerschlak N, Santos F P S

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Everolimus
Share to TSC2 gene
Share to Hodgkin Disease
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Treatment Outcome

Share to Tuberous Sclerosis Complex 2 Protein

Share to Tumor Suppressor Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 27176796
DOI: 10.1038/bcj.2016.25
PMCID: PMC4916294

Genes

TSC2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical response to everolimus in a patient with Hodgkin's lymphoma harboring a TSC2 mutation.PMID 27176796Read ↗

Response and acquired resistance to everolimus in anaplastic thyroid cancer.Semantic proximity Read ↗

Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations.Semantic proximity Read ↗

Exceptional response to everolimus in a novel tuberous sclerosis complex-2 mutation-associated metastatic renal-cell carcinoma.Semantic proximity Read ↗

Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus.Semantic proximity Read ↗

mTOR Inhibitors in Tuberous Sclerosis ComplexSemantic proximity Read ↗

Genome Sequencing Identifies a Basis for Everolimus SensitivitySemantic proximity Read ↗

Effectiveness and safety of everolimus treatment in patients with tuberous sclerosis complex in real-world clinical practiceSemantic proximity Read ↗

Exceptional Response to Pembrolizumab and Trastuzumab in a Heavily Pretreated Patient With HER2-Positive TMB-H and MSI-H Metastatic Breast Cancer.Semantic proximity Read ↗

The Impact of TSC-1 and -2 Mutations on Response to Therapy in Malignant PEComa: A Multicenter Retrospective Analysis.Semantic proximity Read ↗

Response to everolimus is seen in TSC-associated SEGAs and angiomyolipomas independent of mutation type and site in TSC1 and TSC2.Semantic proximity Read ↗

Selective Response to Mammalian Target of Rapamycin Inhibition in a Patient with Metastatic Renal Cell Carcinoma Bearing TSC1 Mutation.Semantic proximity Read ↗

Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.